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Introduction: Microsomal prostaglandin E synthase 1 (mPGES-1) catalyzes the terminal step in the biosynthesis of
PGE2, a critical mediator in the pathophysiology of osteoarthritis (OA). Histone methylation plays an important role
in epigenetic gene regulation. In this study, we investigated the roles of histone H3 lysine 9 (H3K9) methylation in
interleukin 1β (IL-1β)-induced mPGES-1 expression in human chondrocytes.
Methods: Chondrocytes were stimulated with IL-1β, and the expression of mPGES-1 mRNA was evaluated using
real-time RT-PCR. H3K9 methylation and the recruitment of the histone demethylase lysine-specific demethylase 1
(LSD1) to the mPGES-1 promoter were evaluated using chromatin immunoprecipitation assays. The role of LSD1 was
further evaluated using the pharmacological inhibitors tranylcypromine and pargyline and small interfering RNA
(siRNA)-mediated gene silencing. The LSD1 level in cartilage was determined by RT-PCR and immunohistochemistry.
Results: The induction of mPGES-1 expression by IL-1β correlated with decreased levels of mono- and dimethylated
H3K9 at the mPGES-1 promoter. These changes were concomitant with the recruitment of the histone demethylase
LSD1. Treatment with tranylcypromine and pargyline, which are potent inhibitors of LSD1, prevented IL-1β-induced
H3K9 demethylation at the mPGES-1 promoter and expression of mPGES-1. Consistently, LSD1 gene silencing with
siRNA prevented IL-1β-induced H3K9 demethylation and mPGES-1 expression, suggesting that LSD1 mediates
IL-1β-induced mPGES-1 expression via H3K9 demethylation. We show that the level of LSD1 was elevated in OA
compared to normal cartilage.
Conclusion: These results indicate that H3K9 demethylation by LSD1 contributes to IL-1β-induced mPGES-1 expression
and suggest that this pathway could be a potential target for pharmacological intervention in the treatment of OA and
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Osteoarthritis (OA) is the most common joint disease and
is a leading cause of disability in developed countries and
throughout the world [1]. Pathologically, OA is character-
ized by progressive degeneration of articular cartilage, syn-
ovial inflammation and subchondral bone remodeling
[2,3]. These processes are thought to be mediated largely
through excess production of proinflammatory and cata-
bolic mediators, among which prostaglandin E2 (PGE2) is
considered a critical mediator in the pathophysiology of
the disease [2,3]. The beneficial effects of nonsteroidal
anti-inflammatory drugs (NSAIDs), the most widely pre-
scribed drugs worldwide, are attributed to inhibition of
PGE2 production.
PGE2 is the most abundant prostaglandin in the skeletal
system [4]. Excessive levels of PGE2 have been reported in
serum and synovial fluid extracted from patients with OA
and rheumatoid arthritis (RA) [5]. PGE2 contributes to the
pathogenesis of OA through several mechanisms, includ-
ing induction of cartilage proteoglycan degradation [6],
upregulation of matrix metalloproteinase (MMP) activity
and production [7,8] and promotion of chondrocyte apop-
tosis [9]. PGE2 is also a well-known mediator of pain and
neoangiogenesis [10].
The biosynthesis of PGE2 requires two enzymes acting
sequentially. Cyclooxygenase (COX) enzymes convert ara-
chidonic acid (AA) into PGH2, which is in turn isomerized
to PGE2 by PGE synthase (PGES) enzymes. Two isoforms
of the COX enzyme, COX-1 and COX-2, have been identi-
fied. COX-1 is expressed in most tissues and is responsible
for physiological production of PGs. COX-2, in contrast, is
almost undetectable under physiologic conditions, but it is
strongly induced in response to proinflammatory and mito-
gen stimuli [11].
At least three distinct PGES isoforms have been cloned
and characterized, including cytosolic prostaglandin E syn-
thase (cPGES), microsomal prostaglandin E synthase 1
(mPGES-1) and mPGES-2 [12]. cPGES, also called the
heat shock protein–associated protein p23, is constitu-
tively and ubiquitously expressed with, and functionally
coupled with, COX-1, thus promoting immediate produc-
tion of PGE2 [13]. In contrast, mPGES-1, which was ori-
ginally named membrane-bound glutathione S-transferase-
1-like-1 (MGST-L-1), is markedly upregulated by inflam-
matory or mitogenic stimuli and is functionally coupled
with COX-2, thus promoting delayed PGE2 production
[14]. mPGES-2 is constitutively expressed in various cells
and tissues and can be coupled with both COX-1 and
COX-2 [15].
We and others have previously shown that expression of
mPGES-1, but not of cPGES, is elevated in articular tis-
sues taken from patients with OA [16,17] and patients
with RA [18], as well as in the rat adjuvant-induced arth-
ritis model [19], suggesting that aberrant expression of thisenzyme might contribute to the pathogenesis of arthritis.
Importantly, mPGES-1-deficient mice have been shown to
exhibit reduced inflammatory and pain responses and to
be protected against experimental arthritis [20-22] and
bone loss [23].
The proinflammatory cytokines interleukin 1β (IL-1β)
and tumor necrosis factor α (TNF-α) have been shown to
induce mPGES-1 expression in vitro in several tissue and
cell types, including chondrocytes [16,17,24]. However, lit-
tle is known about the molecular mechanisms underlying
the regulation of mPGES-1 expression.
Posttranslational modification of nucleosomal histones,
including acetylation, methylation, phosphorylation and
sumoylation, play important roles in the regulation of gene
transcription through remodeling of chromatin structure
[25,26]. To date, histone acetylation and methylation are
among the most intensively studied and best characterized
modifications of nucleosomal histones. Methylation occurs
on both lysine (K) and arginine residues. In histone H3, dif-
ferent lysine residues (K4, K9, K27, K36 and K79) can be
methylated. Unlike acetylation, which is generally associ-
ated with transcriptional activation, histone lysine methyla-
tion is associated with either gene activation or repression,
depending on the specific residue modified [27-29].
Methylation of histone H3 lysine 4 (H3K4), H3K36 and
H3K79 is generally associated with transcriptionally active
genes, whereas methylation of H3K9 and H3K20 is associ-
ated with transcription silencing [27-29]. Moreover, lysine
methylation can exist in three different states (mono-, di-
and trimethylated), which may bring about additional
regulatory complexity [27-29].
Lysine methylation is controlled by the opposing activ-
ities of lysine methyltransferases (KMTs) and lysine
demethylases (KDMs) [27-29]. There are two classes of ly-
sine demethylases: the amine oxidase-related enzymes and
the Jumonji (JMJ) C-terminal domain–containing en-
zymes. Lysine-specific demethylase 1 (LSD1), also known
as KDM1, p110b, BHC110 or NPAO, was the first histone
demethylase discovered. It belongs to the superfamily of
flavin adenine dinucleotide (FAD)–dependent amine oxi-
dases [30]. Researchers in several studies have demon-
strated that LSD1 modulates gene expression through
demethylation of either H3K4 [31-34] or H3K9 [30,35-38].
In the present study, we demonstrate that the induction
of mPGES-1 expression by IL-1β was associated with de-
creased levels of mono- and dimethylated H3K9 at the
mPGES-1 promoter. These changes correlated with the re-
cruitment of the histone demethylase LSD1. Both pharma-
cological inhibition of LSD1 and small interfering RNA
(siRNA) knockdown prevented IL-1β-induced H3K9 de-
methylation at the mPGES-1 promoter as well as concomi-
tant mPGES-1 protein expression. Furthermore, we show
that the level of LSD1 expression was elevated in OA cartil-
age. These data suggest that modulation of LSD1 in the
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OA and possibly in other conditions associated with in-
creased mPGES-1 expression and PGE2 production.
Methods
Ethical approval
The Clinical Research Ethics Committee of Notre Dame
Hospital approved the study protocol and the use of hu-
man articular tissues. Informed consent was obtained
from each donor or from a family member.
Reagents and antibodies
Recombinant human (rh) IL-1β was obtained from Gen-
zyme (Cambridge, MA, USA). Aprotinin, leupeptin, pep-
statin, phenylmethylsulfonyl fluoride (PMSF), sodium
orthovanadate (Na3VO4), pargyline and tranylcypromine
were purchased from Sigma-Aldrich Canada (Oakville,
ON, Canada). Dulbecco’s modified Eagle’s medium
(DMEM), penicillin and streptomycin, fetal calf serum
(FCS) and TRIzol reagents were supplied by Life Tech-
nologies (Burlington, ON, Canada). Abs against mPGES-1
and cPGES-1 were purchased from Cayman Chemical
(Ann Arbor, MI, USA). The antibody (Ab) against β-actin
was obtained from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Abs against histone H3, mono-, di- and tri-
methylated H3K9, as well as mono-, di- and trimethylated
H3K4, were purchased from EMD Millipore (Billerica,
MA, USA). Abs against LSD1/KDM1, JMJD1A/JHDM2A/
KDM3A, KIAA1718/JHDM1D/KDM7A, PHF8/JHDM1F/
KDM7B and PHF2/JHDM1E/KDM7C were obtained from
Abcam (Cambridge, MA, USA). Polyclonal rabbit anti-
mouse immunoglobulin G (IgG) antibody, coupled with
horseradish peroxidase (HRP) and polyclonal goat anti-
rabbit IgG antibody with HRP, were obtained from
Thermo Fisher Scientific (Rockford, IL, USA).
Specimen selection and chondrocyte culture
Human normal cartilage was obtained at necropsy within
12 hours after death from donors with no history of arth-
ritic disease (n = 13, mean age ± SD= 56 ± 14 years). To en-
sure that only normal tissue was used, cartilage specimens
were thoroughly examined both macroscopically and
microscopically, and only those with neither alteration were
further processed. Human OA cartilage was obtained from
patients undergoing total knee replacement (n = 47, mean
age ± SD= 67 ± 20 years). All OA patients were diagnosed
on the basis of criteria developed by the American College
of Rheumatology Diagnostic Subcommittee for OA [39]. At
the time of surgery, the patients had symptomatic disease
requiring medical treatment in the form of NSAIDs or se-
lective COX-2 inhibitors. Patients who had received any
intraarticular injection of steroids were excluded.
For chondrocyte cultures, cartilage from tibial plateaus
and femoral condyles was used. For immunohistochemicalstudies, only cartilage from femoral condyles was used.
Chondrocytes were released from cartilage by sequential
enzymatic digestion as previously described [40,41]. Cells
were seeded at 3.5 × 105 cells/well in 12-well culture plates
(Costar, Corning, NY, USA) or at 6 to 7 × 105 cells/well in
6-well culture plates in DMEM supplemented with 10%
FCS, and then they were cultivated at 37°C for 48 hours.
The cells were washed and incubated for an additional
24 hours in DMEM containing 0.5% FCS before stimula-
tion with IL-1β alone or in the presence of pharmaco-
logical inhibitors of LSD1. Only first-passage chondrocytes
were used.
Western blot analysis
Chondrocytes were lysed in ice-cold lysis buffer (0.1%
SDS, 0.5% Nonidet P-40; 50 mM Tris-HCl; pH 7.4;
150 mM NaCl; 2 mM ethylenediaminetetraacetic acid;
1 mM PMSF; 10 μg/ml concentrations each of aprotinin,
leupeptin and pepstatin; 1 mM Na3VO4; and 1 mM NaF).
Lysates were sonicated on ice, boiled at 95°C for 5 minutes
and centrifuged at 12,000 rpm for 15 minutes. The protein
concentration of the supernatant was determined using a
bicinchoninic acid protein assay (Thermo Fisher Scien-
tific). Twenty micrograms of total cell lysate were sub-
jected to SDS-PAGE and electrotransferred onto a
nitrocellulose membrane (Bio-Rad Laboratories, Missis-
sauga, ON, Canada). After blocking the cell lysate in
20 mM Tris-HCl, pH 7.5, containing 150 mM NaCl, 0.1%
Tween 20 and 5% (w/v) nonfat dry milk, blots were incu-
bated overnight at 4°C with the primary Ab and washed
with a mixture of Tris-buffered saline, pH 7.5, and 0.1%
Tween 20). The blots were then incubated with HRP-
conjugated secondary Ab (Thermo Fisher Scientific),
washed again, incubated with SuperSignal chemilumines-
cent substrate (Thermo Fisher Scientific) and exposed to
KODAK X-OMAT XAR autoradiography film (Eastman
Kodak, Rochester, NY, USA).
RNA extraction and reverse transcriptase polymerase
chain reaction
Total RNA from stimulated chondrocytes was isolated
using TRIzol reagent (Life Technologies) according to the
manufacturer’s instructions. To remove contaminating
DNA, isolated RNA was treated with RNase-free DNaseI
(Ambion, Austin, TX, USA). The RNA was quantitated
using the RiboGreen RNA assay kit (Molecular Probes,
Eugene, OR, USA), dissolved in diethylpyrocarbonate-
treated H2O and stored at −80°C until use. One micro-
gram of total RNA was reverse-transcribed using Moloney
murine leukemia virus reverse transcriptase (Fermentas,
Burlington, ON, Canada) as detailed in the manufacturer’s
guidelines. One-fiftieth of the reverse transcriptase reac-
tion was analyzed by real-time PCR as described below.
The following primers were used: mPGES-1: sense 5′-G
El Mansouri et al. Arthritis Research & Therapy 2014, 16:R113 Page 4 of 15
http://arthritis-research.com/content/16/3/R113AAGAAGGCCTTTGCCAAC-3′ and antisense 5′-GG
AAGACCAGGAAGTGCATC-3′; MMP-13: sense 5′-TG
AAGCAGTGAAGAAGGAC-3′ and antisense 5′-CTGC
TTTCTCTTGTAGAATC-3′; and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH): sense 5′-CAGAAC
ATCATCCCTGCCTCT-3′ and antisense 5′-GCTTGAC
AAAGTGGTCGTTGAG-3′.
Real-time PCR
Real-time PCR analysis was performed in a total volume
of 50 μl containing template DNA, 200 nM concentra-
tions of sense and antisense primers, 25 μl of SYBR
Green Master Mix (QIAGEN, Mississauga, ON, Canada)
and uracil-N-glycosylase (0.5 units, UNG; Epicentre
Technologies, Madison, WI, USA). After incubation at
50°C for 2 minutes (UNG reaction) and at 95°C for 10 mi-
nutes (UNG inactivation and activation of the AmpliTaq
Gold enzyme (Life Technologies)), the mixtures were sub-
jected to 40 amplification cycles (15 seconds at 95°C for
denaturation and 1 minute for annealing and extension at
60°C). Incorporation of SYBR Green dye into PCR prod-
ucts was monitored in real time using a GeneAmp 5700
Sequence detection system (Applied Biosystems, Foster
City, CA, USA) to enable us to determine the threshold
cycle (CT) at which exponential amplification of the PCR
products began. After PCR, dissociation curves were gen-
erated with one peak, which indicated the specificity of
the amplification. We obtained a CT value from each amp-
lification curve using the software provided by the manu-
facturer (Applied Biosystems).
Relative mRNA expression in chondrocytes was deter-
mined using the ΔΔCT method, as detailed in the manu-
facturer’s guidelines (Applied Biosystems). A ΔCT value
was first calculated by subtracting the CT value for the
housekeeping gene GAPDH from the CT value for each
sample. A ΔΔCT value was then calculated by subtracting
the ΔCT value of the control (unstimulated cells) from the
ΔCT value of each treatment. Fold changes compared with
the control were then calculated using the 2−ΔΔCT method.
Each PCR generated only the expected specific amplicon,
as shown by the melting-temperature profiles of the final
product and by gel electrophoresis of test PCRs. Each
PCR was performed in triplicate on two separate occa-
sions for each independent experiment.
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation (ChIP) experiments
were performed according to the ChIP protocol provided
by EMD Millipore. The data are expressed as percentages
of control (unstimulated cells) or fold changes relative to
control conditions (unstimulated cells) calculated using
the ΔΔCT method as detailed in the manufacturer’s guide-
lines and according to previously published methods
[42,43]. A ΔCT value was first calculated by subtractingthe CT value for the input DNA from the CT value for the
immunoprecipitated sample (ChIP analysis). A ΔΔCT value
was then calculated by subtracting the ΔCT value of the
control from the ΔCT value of each treatment. Fold changes
compared with the control (unstimulated cells) were then
calculated using the 2−ΔΔCT method. The following primer
sequences were used: mPGES-1 promoter: sense 5′-GTT
TGAGGATTTGCCTGGAA-3′ and antisense 5′-CTGC
TCATCACCAGGCTGT-3′; and MMP-13 promoter: sense
5′-ATTTTGCCAGATGGGTTTTG-3′ and antisense 5′-C
TGGGGACTGTTGTCTTTCC-3′. Primers were tested in
a conventional PCR using genomic DNA as the template
and checked on an agarose gel to ensure that the primer
PCRs resulted in a single band of predicted size.
RNA interference
Specific siRNA for LSD1 and scrambled control siRNA
were obtained from Dharmacon (Lafayette, CO, USA).
Chondrocytes were seeded into 6-well plates at 6.105
cells/well and incubated for 24 hours. The cells were
then transfected with 100 nM siRNA using HiPerFect
Transfection Reagent (QIAGEN) according to the man-
ufacturer’s recommendations. The medium was changed
24 hours later, and then the cells were incubated for an
additional 24 hours before stimulation with 100 pg/ml
IL-1β for 2 or 20 hours.
Immunohistochemistry
Cartilage specimens were processed for immunohisto-
chemistry as previously described [40]. The specimens
were fixed in 4% paraformaldehyde and embedded in
paraffin. Sections (5 μm) of paraffin-embedded speci-
mens were deparaffinized in toluene and dehydrated in a
graded series of ethanol. The specimens were then pre-
incubated with chondroitinase ABC (0.25 U/ml in
phosphate-buffered saline (PBS) solution, pH 8.0) for
60 minutes at 37°C, followed by a 30-minute incubation
with Triton X-100 (0.3%) at room temperature. The
slides were then washed in PBS, followed by 2% hydro-
gen peroxide∕methanol, for 15 minutes. They were then
incubated for another 60 minutes with 2% normal serum
(Vector Laboratories, Burlingame, CA, USA) and over-
laid with primary Ab for 18 hours at 4°C in a humidified
chamber. The Ab used was rabbit polyclonal anti-human
Set1A Ab (Bethyl Laboratories, Montgomery, TX, USA),
which was concentrated at 10 μg/ml. Each slide was
washed three times in PBS, pH 7.4, and stained using
the avidin-biotin complex method (VECTASTAIN ABC
Kit; Vector Laboratories). The color was developed with
3,3′-diaminobenzidine (Vector Laboratories) containing
hydrogen peroxide. The slides were counterstained with
eosin. The specificity of staining was evaluated using
preadsorbed Ab (1 hour, 37°C) with a 20-fold molar ex-
cess of protein fragment corresponding to amino acids
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the primary Ab with nonimmune rabbit IgG (Chemicon
International, Temecula, CA, USA), which was used at
the same concentration as the primary Ab. The evalu-
ation of positive-staining chondrocytes was performed
using our previously published method [40]. For each
specimen, six microscopic fields were examined under
40× magnification. The total number of chondrocytes
and the number of chondrocytes staining positive were
evaluated, and the results are expressed as the percent-
age of chondrocytes that stained positive (cell score).
Flavin adenosine dinucleotide quantification
Intracellular FAD was measured using the FAD Assay
and Deproteinizing Sample Preparation Kit (BioVision
Research Products, Mountain View, CA, USA).
Statistical analysis
Data are expressed as the mean ± SD. For chondrocyte
culture studies, statistical significance was assessed by
one-way analysis of variance, followed by the Bonferroni
multiple-comparison post hoc test. The comparison of
LSD1 expression in human and OA cartilage was ana-
lyzed using the two-tailed Student’s t-test. P-values less
than 0.05 were considered statistically significant. All
statistics were generated using GraphPad Prism software
(GraphPad Software, San Diego, CA, USA).
Results
IL-1β decreased H3K9 mono- and dimethylation, but not
trimethylation, at mPGES-1 promoter
First, we examined the effect of IL-1β on mPGES-1
mRNA expression in human OA chondrocytes. The cells
were stimulated with IL-1β for various time periods, and
the levels of mPGES-1 were determined by real-time
RT-PCR. IL-1β-induced changes in mPGES-1 gene ex-
pression are expressed as fold changes over control (un-
treated cells) after normalizing to the internal control
GAPDH. As shown in Figure 1A, treatment with IL-1β
(100 pg/ml) induced mPGES-1 mRNA expression in a
time-dependent manner. mPGES-1 mRNA levels started
to increase gradually at 2 hours after stimulation, were sig-
nificantly increased by 4 hours poststimulation, increased
further at 8 hours and peaked at 24 hours. With the longer
incubation times, we observed a gradual decline in the
mRNA levels starting at 36 hours poststimulation. These
results confirmed previously published data showing that
IL-1β is a potent inducer of mPGES-1 expression in hu-
man OA chondrocytes [16,17,24]. The pattern of MMP-13
gene expression in response to IL-1β was similar to that of
mPGES-1 and hence was used as a control comparator.
In numerous recent studies, researchers have demon-
strated that transcriptional activation of a number of
genes is associated with changes in the methylation stateof H3K9, a critical epigenetic marker for gene silencing
[30,35-38]. To determine whether the induction of
mPGES-1 by IL-1β was associated with changes in the
levels of H3K9 methylation at the mPGES-1 promoter, we
performed ChIP assays using specific Abs for mono-, di-
or trimethylated H3K9.
Chondrocytes were stimulated with IL-1β for different
time periods, and ChIP-enriched DNA was analyzed by
real-time PCR using specific primers spanning the tran-
scription start site (+1), the TATA box and several tran-
scription factor binding sites in the proximal regions of
the mPGES-1 promoter (bp −259 to +10) and MMP-13
promoter (bp −220 to +7). Control Ig and no Ab were
used as controls.
As shown in Figures 1B and 1C, treatment with IL-1β
decreased the levels of mono- and dimethylated H3K9 at
the mPGES-1 promoter in a time-dependent manner.
Their levels began to decrease at 2 hours after stimula-
tion with IL-1β, persisted through 12 to 24 hours and
then increased at 48 hours. In contrast, the levels of
mono- and dimethylated H3K9 at the MMP-13 pro-
moter did not appreciably change under the same condi-
tions (during the treatment) (Figures 1B and 1C),
indicating that the observed modifications at the mPGES-
1 promoter were specific. There were no significant
changes in the levels of trimethylated H3K9 at the
mPGES-1 or MMP-13 promoter at any time analyzed
(Figure 1D). No immunoprecipitable mPGES-1 promoter
DNA was detected with the control Ig or the no-Ab con-
trols (data not shown). The decrease in the levels of
mono- and dimethylated H3K9 at the mPGES-1 promoter
in response to IL-1β paralleled transcriptional induction of
mPGES-1 (Figure 1A), suggesting that diminished levels
of mono- and dimethylated H3K9 might play a key role in
IL-1β-induced mPGES-1 expression.
Next, we investigated the effect of IL-1β on global
H3K9 methylation in chondrocytes. Cells were stimu-
lated with IL-1β for various time periods, and the levels
of H3K9 methylation were measured by Western blot
analysis using specific Abs for mono-, di- and trimethy-
lated H3K9. Figures 1B to 1D demonstrate that the
levels of mono-, di- and trimethylated H3K9 were high
in untreated chondrocytes and that treatment with IL-
1β did not significantly change these levels. These re-
sults indicate that the alterations in H3K9 methylation
seen in ChIP assays were not due to nonspecific global
histone modifications and were specific to the proximal
region of the mPGES-1 promoter.
IL-1β enhanced recruitment of LSD1 to mPGES-1 promoter
Since the induction of mPGES-1 expression by IL-1β
correlated with reduced H3K9 methylation, we hypothe-
sized that IL-1β might mediate this effect by inducing














































































































































Figure 1 Effect of interleukin 1β on histone H3 lysine 9 methylation at the microsomal prostaglandin E synthase 1 promoter. (A)
Osteoarthritis (OA) chondrocytes were treated with 100 pg/ml interleukin 1β (IL-1β) for the indicated time periods. Total RNA was isolated,
reverse-transcribed into cDNA, and microsomal prostaglandin E synthase 1 (mPGES-1), matrix metalloproteinase 13 (MMP-13) and glyceraldehyde
3-phosphate dehydrogenase mRNAs were quantified using real-time PCR. All experiments were performed in triplicate, and negative controls
without template RNA were included in each experiment. The results are expressed as fold changes, assuming 1 as the value of untreated cells, and
represent the mean ± SD of four independent experiments using cells from four different OA donors. *P < 0.05 compared with unstimulated cells.
(B)- through (D) Confluent OA chondrocytes were treated with 100 pg/ml IL-1β for the indicated time periods. Chromatin immunoprecipitation (ChIP)
assays, coupled with real-time PCR, were performed using antibodies specific to mono- (B), di- (C) and trimethylated (D) histone H3 lysine 9 (H3K9).
me1, Monomethylation; me2, Dimethylation; me3, Trimethylation. The results are expressed as percentages of control values (that is, untreated cells)
and are represent the mean ± SD of four independent experiments. For each ChIP assay, the immunoprecipitated DNA was quantitated in triplicate on
two separate occasions. *P < 0.05 compared with unstimulated cells. The lower panels show chondrocytes that were treated as indicated. The levels of
mono-, di- and trimethylated H3K9 and unmodified H3 were evaluated by immunoblotting. The blots are representative of similar results obtained in
four independent experiments in which we used cells from four different OA donors. (E) and (F) Schematic diagrams of the mPGES-1 and MMP-13
promoters showing the locations of the PCR primers (arrows) used in the ChIP analyses.
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whether chondrocytes express the proteins LSD1/KDM1
[30], JMJD1A/JHDM2A/KDM3A [44], KIAA1718/JHD
M1D/KDM7A [45], PHF8/JHDM1F/KDM7B [46] and
PHF2/JHDM1E/KDM7C [47]. We focused on these pro-
teins because they can demethylate H3K9me1 and
H3K9me2, but not H3K9me3. As shown in Figure 2A,
Western blot analyses with nuclear extracts from four
different chondrocyte populations indicated the presence
of the five demethylases in all of the cell populations
tested. Hence, we performed ChIP assays to examinewhether IL-1β would modulate the recruitment of these
demethylases to the mPGES-1 promoter. The results dem-
onstrate that LSD1 was present at the proximal region of
the mPGES-1 promoter (Figure 2B) and that treatment
with IL-1β enhanced its level in a time-dependent manner.
The level started to increase significantly at 2 hours after
IL-1β stimulation, reached a maximum at 12 to 24 hours
and then decreased by 48 hours. With regard to JMJD1A/
JHDM2A/KDM3A, KIAA1718/JHDM1D/KDM7A, PHF8/
JHDM1F/KDM7B and PHF2/JHDM1E/KDM7C, their
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Figure 2 Effect of interleukin 1β on the recruitment of lysine-specific demethylase 1 to the microsomal prostaglandin E synthase 1.
A, nuclear extracts (20 μg) from four different osteoarthritis (OA) chondrocyte populations obtained from four different donors were studied by
Western blot analysis and hybridized to antibodies specific to LSD1/KDM1, JMJD1A/JHDM2A/KDM3A, KIAA1718/JHDM1D/KDM7A, PHF8/JHDM1F/
KDM7B and PHF2/JHDM1E/KDM7C. (B) Confluent OA chondrocytes were treated with 100 pg/ml interleukin 1β (IL-1β) for the indicated time
periods, and chromatin immunoprecipitation (ChIP) assays were performed using a specific antibody against lysine-specific demethylase 1 (LSD1).
The results are expressed as fold changes of LSD1 binding to the microsomal prostaglandin E synthase 1 (mPGES-1) or matrix metalloproteinase
13 (MMP-13) promoter relative to untreated cells and represent the mean ± SD of four independent experiments. *P < 0.05 compared with
unstimulated cells. (C) Confluent OA chondrocytes were treated as described in part (B), and cell lysates were prepared and analyzed for LSD1
protein expression by Western blotting. In the lower panels, the blots were stripped and reprobed with a specific anti-β-actin antibody. The blots
are representative of similar results obtained from four independent experiments using cells from four separate donors.
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plate control (CT ≥38) and IL-1β treatment had no sig-
nificant effect on their recruitment at the mPGES-1
promoter. No immunoprecipitable mPGES-1 promoter
DNA was detected with the control Ig and no-Ab con-
trols (data not shown).
Treatment with IL-1β did not affect the levels of LSD1
protein expression (Figure 2C), suggesting that the re-
cruitment of LSD1 to the mPGES-1 promoter seen with
the ChIP assays was specific and was not due to in-
creased expression of LSD1 protein.
The pattern of LSD1 levels at the mPGES-1 pro-
moter correlated with decreased H3K9 methylation
and is strikingly similar to transcriptional induction of
mPGES-1 expression. This strongly suggests that IL-
1β-induced mPGES-1 expression involves the recruit-
ment of LSD1 and H3K9 methylation.
Inhibition of LSD1 activity prevented IL-1β-induced H3K9
demethylation at mPGES-1 promoter and mPGES-1
protein expression
LSD1 demethylates lysine residue through a FAD-
dependent reaction [30,48]. This reaction is inhibited by
monoamine oxidase inhibitors such as pargyline and
tranylcypromine [35,49,50]. Therefore, we investigated
their effects on IL-1β-induced H3K9 demethylation at
the mPGES-1 promoter and on mPGES-1 protein ex-
pression. Chondrocytes were pretreated with increasing
concentrations of pargyline or tranylcypromine for
1 hour before stimulation with IL-1β for an additional 8
or 24 hours. The levels of H3K9me1 and H3K9me2 atthe mPGES-1 promoter were analyzed using ChIP as-
says with Abs against mono- and dimethylated H3K9.
We found that treatment with either pargyline (Figures 3A
and 3B) or tranylcypromine (Figures 3D and 3E) dose-
dependently prevented IL-1β-reduced H3K9me1 and
H3K9me2 levels, which decreased during transcriptional
activation. However, pargyline and tranylcypromine treat-
ment did not change the level of H3K9me3, which was not
affected during IL-1β-induced mPGES-1 transcription (data
not shown). Accordingly, pretreatment with either pargy-
line or tranylcypromine dose-dependently suppressed IL-
1β-induced mPGES-1 protein expression (Figures 3C and
3F). The inhibition observed was not a result of reduced
cell viability, which was confirmed in a 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (data
not shown). These findings strongly suggest that the LSD1
activity contributes to IL-1β-induced H3K9 demethylation
at the mPGES-1 promoter as well as to mPGES-1 protein
expression.LSD1 silencing with siRNA suppressed IL-1β-induced
H3K9 demethylation at mPGES-1 promoter and
IL-1β-induced mPGES-1 protein expression
To further define the role of LSD1, we determined the ef-
fect of its silencing by siRNA on IL-1β-induced H3K9 de-
methylation at the mPGES-1 promoter and on mPGES-1
protein expression. Chondrocytes were transfected with
the scrambled control siRNA or siRNA for LSD1, and,
after 48 hours of transfection, the cells were either stimu-
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Figure 3 Effect of pargyline and tranylcypromine on interleukin 1β-induced histone H3 lysine 9 demethylation and microsomal
prostaglandin E synthase 1 protein expression. Osteoarthritis (OA) chondrocytes were pretreated with control vehicle (dimethyl sulfoxide) or
increasing concentrations of pargyline (A) through (C) and tranylcypromine (TCP) (D) through (F) for 1 hour prior to stimulation with 100 pg/ml
interleukin 1β (IL-1β) for 8 hours (A, B, D and E) or 24 hours (C) and (F). (A), (B), (D) and (E) Chromatin immunoprecipitation (ChIP) assays,
coupled with real-time PCR, were performed using antibodies specific to mono- and dimethylated histone H3 lysine 9 (H3K9). The results are
expressed as the percentage of control values (that is, untreated cells) and represent the mean ± SD of four independent experiments. For each
ChIP assay, the immunoprecipitated DNA was quantitated in triplicate on two separate occasions. *P < 0.05 compared with IL-1β-treated cells.
TCP, tranylcypromine. (C) and (F) Cell lysates were prepared and analyzed for microsomal prostaglandin E synthase 1 (mPGES-1) protein expression by
Western blotting. In the lower panels, the blots were stripped and reprobed with specific anti-β-actin antibody. The blots are representative of similar
results obtained in four independent experiments using cells from four separate donors. cPGES, Cytosolic prostaglandin E synthase; me1,
Monomethylation; me2, Dimethylation; me3, Trimethylation.
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prevented IL-1β-mediated diminished levels of H3K9me1
and H3K9me2 at the mPGES-1 promoter (Figures 4A and
4B). Furthermore, LSD1 silencing markedly suppressed
IL-1β-induced mPGES-1 expression (Figure 4B). In con-
trast, transfection with scrambled control siRNA had no
effect on either H3K9 demethylation or mPGES-1 expres-
sion. LSD1 protein levels were reduced by as much as 75%
to 80%, confirming gene silencing (Figures 4A and 4B).
Together, these data strongly suggest that LSD1 contrib-
uted to IL-1β-induced mPGES-1 expression through
downregulation of H3K9 mono- and dimethylation.
Effect of IL-1β on H3K9 methylation, LSD1 recruitment
and flavin adenosine dinucleotide levels in normal and
osteoarthritis chondrocytes
OA chondrocytes (n = 3 donors) and normal chondro-
cytes (n = 3 donors) from age-matched donors were
treated with IL-1β for different time periods, and the
levels of H3K9 methylation at the mPGES-1 promoter
were analyzed by performing ChIP assays using specific
Abs for mono-, di- or trimethylated H3K9. We observed
a time-dependent decrease in the level of H3K9me2 andH3K9me1 at the mPGES-1 promoter in OA and normal
chondrocytes, whereas the level of H3K4me3 remained
unchanged (Figures 5A and 5B).
Next, we investigated the effect of IL-1β on LSD1 re-
cruitment at the mPGES-1 promoter in normal and
OA chondrocytes. As shown in Figure 5C, treatment
of normal chondrocytes with IL-1β resulted in LSD1
recruitment at the mPGES-1 promoter, suggesting
that, as observed in OA chondrocytes (Figure 5D), the
H3K9 demethylase involved in H3K9me1 and H3K9me2
demethylation at the mPGES-1 promoter in normal chon-
drocytes is LSD1.
LSD1 utilizes FAD as an essential cofactor in catalyzing
demethylation of mono- and di-methylated H3K9 [30].
We therefore examined whether IL-1β-induced H3K9 de-
methylation and LSD1 recruitment to the mPGES-1 pro-
moter were associated with changes in FAD levels. As
shown in Figures 5E and 5F, treatment of chondrocytes
with IL-1β did not affect the content levels of FAD at
any time point. These data indicate that IL-1-induced
H3K9 demethylation and LSD1 recruitment in human
chondrocytes were not associated with significant
changes in FAD levels.
IL-1 - +         - +        - + 
CTL siRNA        - - +         +        - -
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Figure 4 Effect of lysine-specific demethylase 1 silencing on interleukin 1β–induced histone H3 lysine 9 demethylation at microsomal
prostaglandin E synthase 1 promoter. Osteoarthritis (OA) chondrocytes were transfected with 100 nM control scrambled small interfering RNA
(siRNA) or lysine-specific demethylase 1 (LSD1). At 48 hours posttransfection, cells were left untreated or treated with 100 pg/ml interleukin 1β
(IL-1β) for 8 hours (A) or 24 hours (B). CTL, Control. (A) Chromatin immunoprecipitation (ChIP) assays, coupled with real-time PCR, were performed
using antibodies specific to mono- and dimethylated histone H3 lysine 9 (H3K9). The results are expressed as percentages of control values (that is,
untreated cells), and the data are the mean ± SD of four independent experiments. For each ChIP assay, the immunoprecipitated DNA was quantitated
in triplicate on two separate occasions. *P < 0.05 compared with nontransfected cells stimulated with IL-1β. (B) Cell lysates were prepared and analyzed
for microsomal prostaglandin E synthase 1 (mPGES-1) protein expression by Western blotting. The blots were stripped and reprobed with specific
anti-β-actin antibody. The blots are representative of similar results obtained from four independent experiments using cells from four separate donors.
Knockdown of LSD1 was confirmed by Western blotting using a specific anti-LSD1 antibody (lower panels).
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mPGES-1 promoter
H3K4 methylation is a critical epigenetic marker of tran-
scriptional activation [27-29]. We therefore examined the
effect of IL-1β on H3K4 methylation at the mPGES-1 pro-
moter. As shown in Figure 6, treatment with IL-1β en-
hanced the levels of H3K4 methylation at the mPGES-1
promoter in a time-dependent manner. The levels of
di- and trimethylated H3K4 were significantly enhanced
at 4 hours after IL-1β stimulation, reached a maximum at
12 hours, persisted through 24 hours and decreased at
48 hours. In contrast, the level of monomethylated H3K4
remained almost unchanged following IL-1β stimulation.
The increase in H3K4 di- and trimethylation by IL-1β at
the mPGES-1 promoter paralleled the increased transcrip-
tion of mPGES-1 (Figure 1A), suggesting that, in addition
to H3K9 demethylation, H3K4 methylation also contrib-
uted to IL-1β-induced mPGES-1 expression.
LSD1 levels were elevated in osteoarthritis cartilage
To investigate the expression of LSD1 in vivo, we ana-
lyzed its mRNA levels in total cartilage from healthy do-
nors (n = 10) and OA donors (n = 10) using real-time
quantitative RT-PCR. As shown in Figure 7A, the level
of LSD1 mRNA was about 1.7-fold higher in OA cartil-
age compared with normal cartilage.(mPGES-1) catalyzes the terminal step in the biosyn-
thesis of PGE2, a critical mediator in the pathophysiology
of osteoarthritis (OA). Histone methylation plays an im-
portant role in epigenetic gene regulation. In this study,
we investigated the roles of histone H3 lysine 9 (H3K9).
Next, we used immunohistochemistry to analyze the ex-
pression level of LSD1 protein. Typical normal and OA
cartilage sections immunostained for LSD1 and the corre-
sponding negative control are shown in Figures 7B to 7E.
LSD1 expression was seen in normal and OA cartilage in
all superficial, middle and deep layers of the articular car-
tilage, and we observed that the expression levels were
relatively high in the superficial and middle zones.
Statistical calculation the cell score revealed that the
percentage of cells expressing LSD1 was approximately
1.8-fold higher in OA cartilage (n = 10) than in normal
cartilage (n = 10) (Figure 7G). The specificity of the
staining was confirmed using an Ab that had been pre-
adsorbed (1 hour at 37°C) with a 20-fold molar excess of
the peptide antigen or nonimmune control IgG (data
not shown). Together, these data indicate that the ex-
pression level of LSD1 was increased in OA cartilage.
Discussion
Histone methylation and demethylation play important




Figure 5 Effect of interleukin 1 on histone H3 lysine 9 methylation, lysine-specific demethylase 1 recruitment and flavin adenine
dinucleotide levels in normal and osteoarthritis chondrocytes. Normal (A) and (C) and osteoarthritis (OA) (B) and (D) chondrocytes were
treated with 100 pg/ml interleukin 1β (IL-1β) for the indicated time periods. Chromatin immunoprecipitation (ChIP) assays, coupled with real-time
PCR, were performed using antibodies specific to mono-, di- and trimethylated histone H3 lysine 9 (H3K9) (A) and (B) and lysine-specific
demethylase 1 (LSD1) (C) and (D). The results are expressed as percentages of control values (that is, untreated cells) or fold changes, and the
data are the mean ± SD of three independent experiments using cells from three different donors. *P < 0.05 compared with unstimulated cells.
Normal (E) and OA (F) chondrocytes were treated as indicated, and the levels of flavin adenine dinucleotide (FAD) were determined using a FAD
assay kit. The results are expressed in picomolar units per 106 cells, and the data are the mean ± SD of three independent experiments using cells
from three different donors. me1, Monomethylation; me2, Dimethylation; me3, Trimethylation.
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http://arthritis-research.com/content/16/3/R113may positively or negatively regulate gene expression, de-
pending on which residue is modified and how many
methyl groups are added. H3K9 methylation usually sup-
presses transcription, whereas H3K4 methylation generally
activates transcription [27-29].
In the present study, we show that IL-1β-induced
mPGES-1 expression in human OA chondrocytes corre-
lated with reduced levels of H3K9me1 and H3K9me2 at
the mPGES-1 promoter. We identified LSD1 as the respon-
sible demethylase, since inhibition of LSD1 activity or its
knockdown prevented IL-1β-induced H3K9 demethylation
and mPGES-1 expression. We also demonstrate that LSD1
levels were elevated in the superficial and middle zones of
OA cartilage. These data indicate that H3K9 demethylation
by LSD1 contributes to IL-1β-induced mPGES-1 expres-
sion and suggest that this pathway might be a potential tar-
get for modulation of PGE2 levels.
Our finding that the induction of mPGES-1 expression
by IL-1β was associated with demethylation of H3K9 is
consistent with the results of several recent studies in which
researchers showed that the transcriptional activation of anumber of inducible inflammatory genes correlated with
decreased methylation of H3K9 at target promoters. For in-
stance, the induction of IL-12p40, the macrophage-derived
chemokine, as well as Epstein-Barr virus–induced molecule
1 ligand chemokine, by lipopolysaccharide (LPS) in den-
dritic cells was observed to be accompanied by loss of
H3K9 methylation at the three gene promoters [51]. Re-
duced H3K9 methylation was also observed at the IL-1β
and TNF-α promoters in LPS-treated THP-1 cells [52,53],
at the MMP-9 promoter in phorbol 12-myristate 13-
acetate–treated HeLa cells [54] and at the NF-κB-p65 pro-
moter in a model of transient hyperglycemia in bovine
aortic endothelial cells [55]. Similarly, H3K9 methylation
was reduced upon stimulation of murine vascular smooth
muscle cells with TNF-α at the promoters of IL-1β, macro-
phage colony-stimulating factor 1 and monocyte chemo-
attractant protein 1 [56]. In line with this finding, and in
the context of cancer, transcriptional activation of several
genes was associated with decreased H3K9 methylation, in-
cluding androgen receptor–induced, prostate-specific anti-
gen expression in LNCaP cells [35], as well as estrogen
Figure 6 Effect of interleukin 1β on histone H3 lysine 4
methylation at microsomal prostaglandin E synthase 1
promoter. Osteoarthritis (OA) chondrocytes were treated with
100 pg/ml interleukin 1β (IL-1β) for the indicated time periods, and
chromatin immunoprecipitation (ChIP) assays were performed using
antibodies specific to mono-, di- and trimethylated histone H3 lysine 4
(H3K4). The results are expressed as fold changes relative to control
(that is unstimulated cells), and the data are the mean ± SD of three
independent experiments using cells from four different donors. For
each ChIP assay, the immunoprecipitated DNA was quantitated in
triplicate on two separate occasions. *P < 0.05 compared with
unstimulated cells. me1, Monomethylation; me2, Dimethylation;
me3, Trimethylation.
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http://arthritis-research.com/content/16/3/R113receptor-induced GREB1 expression in MCF7 cells [37].
Loss of H3K9 methylation during varicella zoster virus re-
activation from latency has also been reported [38].
Several H3K9me1/2 demethylases have been identified,
including LSD1/KDM1 [57], JMJD1A/JHDM2A/KDM3A
[44], KIAA1718/JHDM1D/KDM7A [45], PHF8/JHDM1F/
KDM7B [46] and PHF2/JHDM1E/KDM7C [47]. We
therefore sought to identify which of these demethylases
might be involved in the reduction of H3K9me1 and
H3K9me2 levels at the mPGES-1 promoter.
Treatment with IL-1β increased the level of LSD1 at
the mPGES-1 promoter, but it had no effect on the re-
cruitment of the other demethylases, suggesting that the
H3K9 demethylase that is involved in H3K9me1 and
H3K9me2 demethylation at the mPGES-1 promoter is
LSD1. It is noteworthy that the recruitment of LSD1 at
the mPGES-1 promoter coincides with decreased H3K9
mono- and dimethylation and correlates well with the
increased transcription of mPGES-1. Taken together,
these results strongly suggest that LSD1 recruitment to
the mPGES-1 promoter and H3K9 demethylation con-
tribute to IL-1β-induced mPGES-1 expression.
Having established that LSD1 is recruited to the
mPGES-1 promoter, we next examined the effect of its
pharmacological inhibition or silencing on IL-1β-induced
H3K9 demethylation and mPGES-1 expression. The
amino oxidase inhibitors tranylcypromine and pargyline,
known as potent inhibitors of LSD1 activity, preventedboth IL-1β-induced H3K9 demethylation at the
mPGES-1 promoter and IL-1β-induced mPGES-1 pro-
tein expression. Furthermore, siRNA-mediated LSD1
knockdown suppressed IL-1β-induced H3K9 demethyl-
ation and concomitant mPGES-1 protein expression.
These results further support the model in which LSD1
contributes to IL-1β-induced mPGES-1 expression
through H3K9 demethylation.
Our finding that H3K9 demethylation by LSD1 acti-
vates mPGES-1 expression extends similar findings
showing transcriptional activation of a number of genes
by LSD1. For instance, a genome-wide ChIP assay based
on DNA selection and ligation analysis in MCF7 cells
treated with 17β-estradiol revealed the presence of LSD1
at 42% of all polymerase II–positive promoters and that
74% of LSD1-positive genes were expressed [37]. More-
over, LSD1 was reported to demethylate H3K9 and to
mediate ligand-dependent transcription of both andro-
gen receptor– and estrogen receptor–dependent genes
[35,37]. LSD1 was also shown to act as a transcriptional
activator during lytic replication of the herpes simplex
virus [38], the expression of MMP-9 in retinal endothe-
lial cells [58] and the expression of vascular endothelial
growth factor in prostate cancer cells [59].
As stated above, H3K9me1 and H3K9me2 can also be
demethylated by JMJD1A/HDM2A/KDM3A [44], KIAA
1718/JHDM1D/KDM7A [45], PHF8/JHDM1F/KDM7B
[46] and PHF2/JHDM1E/KDM7C [47]. Although we
failed to detect the recruitment of these enzymes at the
mPGES-1 promoter in our ChIP analysis, we cannot ex-
clude their involvement through binding to other regions
of the mPGES-1 promoter, which we did not analyze in
the present study. Moreover, our results, which are con-
sistent with key roles of H3K9 demethylation in IL-1β-
induced mPGES-1 expression, do not rule out the
possibility that changes in the methylation status of other
residues might also participate in IL-1β-induced mPGES-1
expression. Indeed, methylation of H3K4, H3K27, H3K36
and H3K79 is known to modulate gene transcription.
Our ChIP findings demonstrate the occupancy of LSD1
at the mPGES-1 promoter in IL-1β-treated cells. However,
it is unclear how LSD1 is recruited to the mPGES-1 pro-
moter. One possibility is that LSD1 is recruited to the
mPGES-1 promoter by transcriptional regulatory cofac-
tors. Such a mechanism has been reported by Liang et al.,
who demonstrated that the expression of viral immediate
early genes in herpes simplex virus and varicella zoster
virus involves recruitment of LSD1 by the cellular tran-
scriptional co-activator, host cell factor 1, to viral immedi-
ate early promoters [38].
Another possibility is that LSD1 is recruited to the
mPGES-1 promoter by transcription factors that play key
roles in its transcriptional activation, such as hypoxia-
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Figure 7 Expression of lysine-specific demethylase 1 protein in human normal and osteoarthritis cartilage. (A) RNA was extracted from
normal cartilage (n = 10) and osteoarthritis (OA) cartilage (n = 10), reverse-transcribed into cDNA and processed for real-time PCR. The threshold cycle
values were converted to the number of molecules. The data are expressed as copies of the gene’s mRNA detected per 10,000 glyceraldehyde
3-phosphate dehydrogenase (GAPDH) copies. *P < 0.05 versus normal samples. Representative immunostained images of human normal cartilage (B)
and OA cartilage (C) for lysine-specific demethylase 1 (LSD1) protein are shown. (D) and (E) Higher-magnification views of the areas within the
rectangles in (B) and (C), respectively. The arrow shows postitive expression of LSD1. (F) Cartilage specimens treated with the anti-LSD1 antibody that
was preadsorbed with a 20-fold molar excess of the protein fragment corresponding to amino acids 834 to 852 of human LSD1 protein (control for
staining specificity). (G) Percentage of chondrocytes expressing LSD1 in normal and OA cartilage. The data are the mean ± SD of 10 normal and 10 OA
specimens. *P < 0.05 versus normal cartilage.
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http://arthritis-research.com/content/16/3/R113(KLF5) transcription factor [61]. Indeed, LSD1 has been
shown to physically associate with HIF1α in melanoma in-
hibitory activity human pancreatic carcinoma MIA PaCa-
2 cells [62] and with KLF5 in embryonic stem cells [63].
Therefore, it is possible that these transcription factors dir-
ect LSD1 to the mPGES-1 promoter. In this context,
LSD1 has been shown to be recruited by the androgen re-
ceptor and to stimulate transcription through H3K9
demethylation [35]. The transcription factor TLX, an es-
sential neural stem cell regulator, has also been reported
to mediate LSD1 recruitment to the promoters of TLX
target genes in neural stem cells [64] and Y79 retinoblast-
oma cells [65].We also demonstrate that the induction of mPGES-1 by
IL-1β was associated with H3K4 methylation. This extends
similar previous findings showing H3K4 methylation at
the promoters of several inflammatory genes, including in-
ducible nitric oxide synthase and COX-2, in human chon-
drocytes [40]. The increased level of H3K4 methylation at
the mPGES-1 promoter might rely on the ability of LSD1
to anchor other factors at the mPGES-1 promoter rather
than on its own enzymatic activity. Indeed, LSD1 is usually
found as part of a multiprotein complex with several dis-
tinct enzymatic activities, including transcription factors,
other demethylases and histone methyltransferases. For
instance, Liang et al. reported that the activation of α-
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http://arthritis-research.com/content/16/3/R113herpesvirus lytic replication and its reactivation from la-
tency involve H3K9 demethylation and H3K4 trimethyla-
tion through recruitment of (1) a multiprotein complex
containing LSD1 and (2) the H3K4 methyltransferases
mixed lineage leukemia 1 (MLL1) and Set1A [38]. Simi-
larly, Le Douce et al. showed that the recruitment of
LSD1 at the HIV-1 proximal promoter is associated with
both H3K4me3 and H3K9me3 epigenetic markers through
corecruitment of LSD1 and the histone methyltransferase
hSET1 at the integrated provirus [66]. Wang et al. dem-
onstrated that LSD1 associates with the MLL1 complex,
which mediates H3K4 trimethylation at the growth hor-
mone promoter during developmental activation [67].
Therefore, it is likely that multiprotein complexes such
as these, which contain LSD1 and histone methylases,
coordinate H3K4/H3K9 methylation and cooperate to
mediate IL-1β-induced mPGES-1 expression.
H3K9 demethylation may mediate IL-1β-induced
mPGES-1 expression through several nonexclusive mecha-
nisms. H3K9 demethylation may promote transcriptional
activation by enhancing lysine acetylation and allowing
better access to DNA for transcription factors and RNA
polymerase. Such a mechanism was reported by Escoubet-
Lozach et al., who showed that LSD1 participates in
pomalidomide-induced p21WAF expression in Burkitt’s
lymphoma cells by favoring H3K9 acetylation [68]. Simi-
larly, Zhong et al. reported that LSD1-mediated MMP-9
expression in diabetes involves increased H3K9 acetylation
[58]. H3K9 demethylation can also contribute to IL-1β-
induced mPGES-1 expression by preventing DNA methyl-
transferase recruitment and local DNA methylation, which
is often associated with transcriptional silencing. Indeed,
H3K9 methylation is required for DNA methylation
[69,70]. In addition, H3K9 demethylation can participate in
IL-1β-induced mPGES-1 expression by modifying the bind-
ing of chromatin factors and/or regulators. In this context,
El Gazzar et al. demonstrated, in a THP-1 model of endo-
toxin tolerance, that the loss of H3K9 methylation at the
TNF-α promoter induced gene expression by decreasing
the level of heterochromatin protein 1 α, which is known
for its role in gene silencing [53]. In the present study, we
found no evidence of either of these mechanisms. Add-
itional biochemical analyses are clearly warranted to resolve
this issue.
We show here that LSD1 expression was higher in OA
cartilage than in normal tissue. Interestingly, we and
others have previously reported elevated levels of mPGES-
1 in OA tissue [16,17,24], suggesting that high expression
of LSD1 may be responsible for increased levels of
mPGES-1. These data, together with our findings that
LSD1 mediates IL-induced mPGES-1 expression in cul-
tured chondrocytes, suggest that elevated levels of LSD1
may be part of the mechanisms responsible for increased
mPGES-1 expression in OA cartilage.Conclusions
The results of the present study demonstrate that the
histone demethylase LSD1 contributes to IL-1β-induced
mPGES-1 expression in human chondrocytes through
H3K9 demethylation. Our findings thus provide insight
into the regulatory mechanisms underlying mPGES-1
expression and may have implications for the design of
new anti-OA and anti-inflammatory drugs.
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